FibroGen Inc (NASDAQ: FGEN) on Monday, plunged -2.99% from the previous trading day, before settling in for the closing price of $0.31. Within the past 52 weeks, FGEN’s price has moved between $0.30 and $2.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.51% over the last five years. The company achieved an average annual earnings per share of 65.03%. With a float of $93.37 million, this company’s outstanding shares have now reached $98.77 million.
The firm has a total of 486 workers. Let’s measure their productivity. In terms of profitability, gross margin is 76.65%, operating margin of -91.86%, and the pretax margin is -98.64%.
FibroGen Inc (FGEN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of FibroGen Inc is 7.00%, while institutional ownership is 57.14%. The most recent insider transaction that took place on Jun 12 ’24, was worth 25,884. In this transaction Chief Medical Officer of this company bought 22,123 shares at a rate of $1.17, taking the stock ownership to the 82,123 shares. Before that another transaction happened on Mar 07 ’24, when Company’s CEO bought 50,000 for $1.91, making the entire transaction worth $95,470. This insider now owns 470,178 shares in total.
FibroGen Inc (FGEN) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.65 earnings per share (EPS) for the period topping the consensus outlook (set at -0.68) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.03% per share during the next fiscal year.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
FibroGen Inc (FGEN) is currently performing well based on its current performance indicators. A quick ratio of 1.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
Analysing the last 5-days average volume posted by the [FibroGen Inc, FGEN], we can find that recorded value of 1.8 million was lower than the volume posted last year of 2.27 million. As of the previous 9 days, the stock’s Stochastic %D was 2.90%. Additionally, its Average True Range was 0.03.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 0.25%, which indicates a significant decrease from 2.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.45% in the past 14 days, which was lower than the 139.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3810, while its 200-day Moving Average is $1.1111. Now, the first resistance to watch is $0.3206. This is followed by the second major resistance level at $0.3425. The third major resistance level sits at $0.3549. If the price goes on to break the first support level at $0.2863, it is likely to go to the next support level at $0.2739. Now, if the price goes above the second support level, the third support stands at $0.2520.
FibroGen Inc (NASDAQ: FGEN) Key Stats
Market capitalization of the company is 30.00 million based on 99,474K outstanding shares. Right now, sales total 147,750 K and income totals -284,230 K. The company made 50,640 K in profit during its latest quarter, and -15,540 K in sales during its previous quarter.
